Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Genetic  is the fastest growing sector, North America is the largest market

The global precision psychiatry market is projected to grow from USD 1.27 billion in 2025 to USD 2.93 billion by 2031, achieving a 14.95% CAGR. This medical approach integrates individual biological data, like genetic and metabolic biomarkers, with clinical information to customize mental health treatments. Key growth drivers include the rising global prevalence of complex mental disorders and the advancement of genomic sequencing, which enables more precise patient stratification. A surge in R&D for novel therapeutic targets, with over 160 mental health treatments in development in 2025, further supports this growth. However, a significant challenge remains: the high capital investment required to integrate precision tools, such as genetic profiling and data analysis, into healthcare infrastructures, potentially limiting accessibility and widespread adoption, especially in resource-constrained systems.

Market Drivers

The integration of AI and machine learning in diagnostics is reshaping the precision psychiatry market by enabling the analysis of vast datasets to identify patient-specific therapeutic responses, synthesizing genomic, transcriptomic, and clinical data for biologically validated treatment protocols. The rapid commercial expansion of AI-enabled precision medicine platforms is evident, with companies like Tempus AI reporting significant revenue increases, such as an 89.6% year-over-year growth to $314.6 million in Q2 2025 driven by genomics and data services adoption. Concurrently, the increasing clinical adoption of pharmacogenomic testing is driving market growth, as clinicians aim to optimize medication selection and reduce adverse drug reactions for the over 1 billion people worldwide living with a mental disorder in 2025. These tests analyze genetic variations affecting drug metabolism, reducing inefficient trial-and-error prescribing, as demonstrated by an 8% year-over-year growth in Myriad Genetics' GeneSight test volume in Q3 2025 despite reimbursement challenges.

Market Challenges

A significant challenge to the precision psychiatry market's expansion is the substantial capital investment required for integrating its tools. This field depends on advanced genomic sequencing and complex data analysis, both demanding costly technological infrastructure and specialized staff. Such high costs create a barrier to entry, especially for providers in developing regions or publicly funded systems with limited budgets, leading to adoption primarily by well-funded private institutions and fragmenting the global market. This issue is intensified by severe underfunding in global mental healthcare; in 2025, median government spending on mental health was only 2% of total health budgets. This chronic underinvestment directly hinders healthcare systems from acquiring and maintaining necessary sophisticated diagnostic tools, thereby decelerating market growth and limiting the widespread application of personalized therapeutic strategies.

Market Trends

A significant trend is the application of precision medicine frameworks to psychedelic therapeutics, moving towards biomarker-guided protocols rather than broad-spectrum administration. This involves using genetic and neurophysiological data to identify patients most likely to benefit from compounds like psilocybin and neuroplastogens, optimizing efficacy and safety.

Commercial confidence in this approach is highlighted by high-value deals, such as AbbVie's acquisition of Gilgamesh Pharmaceuticals’ precision psychedelic program for up to $1.2 billion in August 2025. Concurrently, the proliferation of digital phenotyping through wearables and mobile devices is setting a new standard for continuous, objective patient monitoring. This allows clinicians to collect real-time behavioral data (e.g., sleep, activity, social interaction) to create detailed digital phenotypes that complement traditional assessments. This integration of longitudinal real-world data facilitates early relapse detection and refines personalized treatment plans, a methodology supported by sustained funding for specialized firms like Alto Neuroscience, which maintained $138.3 million in cash in Q3 2025 to advance its precision psychiatry platform incorporating wearable metrics.

Key Market Players

• Johnson & Johnson Services, Inc.
• Roche Holding AG
• Eli Lilly and Company
• Pfizer Inc.
• H. Lundbeck A/S
• Helsinn Group
• Takeda Pharmaceutical Company Limited
• Otsuka Holdings Co., Ltd.
• BioXcel Therapeutics, Inc.
• Neurocrine Biosciences, Inc.

Report Scope

In this report, the Global Precision Psychiatry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Psychiatry Market, by Biomarkers:

• Genetic
• Protein

Precision Psychiatry Market, by Sample:

• Blood Based
• Non-Blood-Based

Precision Psychiatry Market, by Technology:

• Sequencing
• Polymerase Chain Reaction
• Microarray
• Immunoassay
• Others

Precision Psychiatry Market, by Application:

• Alzheimer’s Disease
• Parkinson’s Disease
• Autism
• Depression
• Others

Precision Psychiatry Market, by End User:

• Hospital & Clinics
• Academic & Research Institutions
• Others

Precision Psychiatry Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Psychiatry Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.